

# amfAR

MAKING AIDS HISTORY



2016 Annual Report

amfAR, The Foundation for AIDS Research

# Contents

<b>amfAR in 2016</b>	01
<hr/>	
<b>Grants, Fellowships, and Awards</b>	07
Research Grants, Fellowships, and Awards	
TREAT Asia Grants and Awards	
GMT Initiative Awards	
Public Policy Awards	
<hr/>	
<b>Financial Highlights</b>	13
<hr/>	
<b>Leadership and Advisory Committees</b>	15
Board of Trustees	
Scientific Advisory Committee	
Program Advisory Council	
Management Group	

**amfAR, The Foundation for AIDS Research,  
is dedicated to ending the global AIDS  
epidemic through innovative research.**



amfAR CEO Kevin Robert Frost flanked by Dr. Paul Volberding, director of the amfAR Institute for HIV Cure Research (left), and amfAR Chairman Kenneth Cole

## Research

### Countdown to a Cure for AIDS

In 2015, amfAR announced a \$100 million investment strategy to support its Countdown to a Cure for AIDS initiative, which is aimed at developing the scientific basis for a cure by 2020. The strategy represents an unprecedented expansion of amfAR's grant making and is designed to provide support to any scientist or team of investigators for any research idea with the potential to advance the search for a cure, at any stage of its development.

In just the first 24 months of the initiative, amfAR has supported 139 principal investigators and key personnel in 16 U.S. states and nine other countries around the world. Structured to provide sustained support for a wide range of studies that advance both emerging and established ideas, the strategy comprises the following components:

- ▶ **The amfAR Institute for HIV Cure Research**, established in 2016 with a \$20 million grant over five years to the University of California, San Francisco (UCSF), is the cornerstone of amfAR's cure research efforts.
- ▶ **Innovation Grants**, two-year awards of up to \$200,000 each that enable researchers to test innovative ideas supported by limited preliminary data.
- ▶ **Impact Grants** of up to \$2 million each over four years support the in-depth development of concepts already underpinned by preliminary data showing genuine potential for achieving a cure.
- ▶ **Investment Grants** are aimed at recruiting the experience and expertise of scientists from outside the field of HIV. These \$1 million grants are awarded over a four-year period. Grantees may have expertise in fields such as cancer, neuroscience, or inflammatory disease that can directly inform efforts to cure HIV.

- ▶ **ARCHE**, the amfAR Research Consortium on HIV Eradication, was launched in 2010. It supports collaborative teams of scientists in the U.S. and around the world working on a range of HIV cure strategies.
- ▶ **The Opportunity Fund** is a funding mechanism that enables amfAR to respond quickly to emerging and unforeseen research opportunities.

### Innovation Grants

In June 2016, amfAR announced a new round of Innovation Grants, totaling close to \$1.4 million, to allow scientists to better understand why HIV persists in the body despite effective antiretroviral therapy and pursue novel pathways to a cure. The grants were supported in part by the Foundation for AIDS and Immune Research (FAIR). Among the grantees are Dr. Jonathan Karn of Case Western Reserve University in Cleveland, who is aiming to develop a more accurate, cost-effective, and efficient way to measure the size of the viral reservoir; Dr. Maud Mavigner of Emory University in Atlanta, who is conducting a comprehensive study to identify the most accurate methods to measure the viral reservoir in rhesus macaques infected with SIV (the simian form of HIV); and Dr. Celsa Spina of the University of California, San Diego, who is studying how and where HIV inserts itself into our DNA, enabling it to establish the hidden viral reservoir.

### Investment Grants

In January 2016, amfAR awarded \$1 million each over four years to Harvard physicist Dr. David Weitz and bioengineer and polymer scientist Dr. Alexander Zelikin of Aarhus University in Denmark. The two are collaborating with leading HIV researchers Drs. Bruce Walker and Martin Tolstrup at Harvard and Aarhus, respectively, in

their efforts to eradicate the viral reservoir, which is considered the principal barrier to curing HIV.


### **ARCHE (amfAR Research Consortium on HIV Eradication)**

In October 2015, amfAR provided \$850,000 of renewal ARCHE funding to a consortium of European researchers who aim to replicate the case of the “Berlin patient,” the first and only person known to have been cured of HIV. Diagnosed with leukemia, the patient was given a stem cell transplant with a twist: the cells he received were taken from a donor with a rare genetic mutation conferring resistance to HIV infection. Led by Dr. Javier Martínez-Picado of IrsiCaixa in Spain and Dr. Annemarie Wensing of University Medical Center Utrecht in the Netherlands, the team has already identified a group of patients who have undergone transplants and continues to monitor their progress in the hopes of generating new knowledge that can inform more widely applicable interventions.

amfAR also awarded a \$672,000 ARCHE grant in June 2016 to support a research team led by Dr. Timothy Schacker of the University of Minnesota, Minneapolis. Schacker is collaborating with a pair of leading investigators from the amfAR Institute for HIV Cure Research, Drs. Steven Deeks and Peter Hunt of the University of California, San Francisco (UCSF), to address one of the greatest challenges in HIV cure research: how to establish whether a person has been cured.

### **Mathilde Krim Fellowships**

In October 2015, amfAR awarded a total of \$600,000 in Mathilde Krim Fellowships in Basic Biomedical Research, which provide funding for exceptional young researchers who are new to the field of HIV/AIDS research. The program, which was created in 2008 in honor of amfAR’s Founding Chairman Dr. Mathilde Krim, has achieved spectacular results, including numerous published studies in major scientific journals. Each Krim Fellow receives \$150,000 over two years.



amfAR Institute for HIV Cure Research scientist Dr. Nadia Roan of the University of California, San Francisco (UCSF)

The 2016 fellows are Dr. Luis Agosto of Boston Medical Center, who is exploring one of the mechanisms that perpetuates the viral reservoir, with the goal of understanding how the virus evades the immune system; Dr. Liang Shan of Yale University, who is using a humanized mouse model to test the efficacy of latency reversing



Dr. Javier Martínez-Picado of IrsiCaixa in Spain

drugs, studying their ability to reactivate HIV so that the immune system can kill those cells that harbor the virus; Dr. Louise Scharf of the California Institute of Technology in Pasadena, who is studying the molecular structure of broadly neutralizing antibodies isolated from two HIV-infected patients to better understand how these powerful antibodies can help in the development of a vaccine against the virus; and Dr. Amit Sharma of the Fred Hutchinson Cancer Research Center in Seattle, who is investigating how rhesus macaques can be better utilized as an animal model in HIV vaccine studies.

### **Published Research**

Research studies make the greatest impact on the HIV/AIDS field and on the broader scientific community when they are published in scientific journals. In FY2016, 64 scientific publications resulted from amfAR-funded research.

### **HIV Cure Summit**

In December 2015, amfAR held its second annual HIV Cure Summit at the University of California, San Francisco (UCSF), where leading amfAR-funded HIV cure researchers reported on their progress and discussed the scientific challenges that continue to stand in the way of a cure. The summit followed a November 30 press conference announcing the establishment of the amfAR Institute for HIV Cure Research with a \$20 million grant over five years to UCSF. Speaking at the summit, Drs. Warner Greene, Mike McCune, Satish Pillai, and Steven Deeks addressed the four pillars of HIV cure research: charting the locations of latent HIV reservoirs; understanding how these pockets of virus are established and maintained; recording the amount of virus they contain; and finding a way to eliminate them.

## Think Tanks

In March 2016, amfAR hosted a think tank in Memphis, TN, on measuring the latent HIV reservoir. One of the central challenges in determining whether a person has been cured is measuring small amounts of virus in difficult-to-find niches. The researchers discussed multiple approaches to address the issue and helped design a project that amfAR funded in June 2016, which is being led by think tank participant Dr. Timothy Schacker of the University of Minnesota, Minneapolis.

amfAR hosted another think tank in Portland, OR, in June 2016, on gene therapy approaches to curing HIV. While pharmacological and immunological approaches remain the dominant cure strategies, the case of the “Berlin patient”—the first and only person known to have been cured of HIV—points to the promise of gene therapy. The 10 researchers discussed the various gene therapy strategies currently being pursued and developed recommendations for further advancing the field.

## TREAT Asia

amfAR’s TREAT Asia (Therapeutics Research, Education, and AIDS Training in Asia) program is a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of HIV treatments to adults and children across the Asia-Pacific through research, education, and advocacy of evidence-based HIV-related policies. The TREAT Asia Network encompasses 21 adult and 20 pediatric sites throughout the region, which collaborate on a variety of projects. TREAT Asia scientists produced a record 34 publications in peer-reviewed medical journals in 2016.

## Gathering Critical Information

TREAT Asia pioneered the region’s first adult observational database for HIV/AIDS—the TREAT Asia HIV Observational Database (TAHOD)—which now includes anonymous data collected from approximately 10,000 patients at 21 clinical sites in 12 countries. The information gathered and analyzed through the



Participants at the May 2016 hepatitis C and HIV co-infection treatment training in Bangkok

database informs the development of more effective research and treatment programs, and helps define treatment standards specific to HIV/AIDS in Asia. The TAHOD-Lite database, launched by TREAT Asia in 2015, includes more basic data but from a much larger proportion of the HIV-positive patients seen at participating sites.

## A Global Collaboration

For the past 10 years, amfAR’s TREAT Asia program has been leading the Asia-Pacific region’s involvement in the U.S. National Institutes of Health’s (NIH’s) global HIV consortium, IeDEA—the International Epidemiologic Databases to Evaluate AIDS. In 2016, amfAR successfully re-competed for funding for a new five-year cycle. Studies will be conducted across 58 institutions in 13 countries to address emerging and critical issues facing people living with HIV who are transitioning from pediatric to adolescent care, and aging into older adults.

The new funding will also expand TREAT Asia’s research portfolio to evaluate mental health issues for adolescents, explore how amphetamine use impacts HIV risk behaviors among men who have sex with men and transgender individuals, and enhance the use of eHealth technologies to engage and retain people in treatment programs.

## Improving Care for Children

TREAT Asia’s Pediatric Network includes 20 sites in six countries; these sites share information and best practices in an effort to improve the quality of pediatric care in the region. The TREAT Asia Pediatric HIV Observational Database was modeled on the adult database and includes data from more than 6,400 pediatric patients in Cambodia, India, Indonesia, Malaysia, Thailand, and Vietnam.

## Adolescent Research

There has been growing recognition that the global HIV community has not done enough to prepare patients, families, and providers for the transition of children into adult life and from pediatric to adult HIV care. TREAT Asia is helping to develop and fund adolescent transition programs with the Children and Youth Program of SEARCH (South East Asia Research Collaboration on HIV) at the Thai Red Cross AIDS Research Centre (TRC-ARC) with additional funding from LIFE+ and the International AIDS Society’s Collaboration on Paediatric HIV Education and Research (CIPHER) initiative. In 2016, TREAT Asia/amfAR was awarded a two-year Developmental Research Grant by the National Institutes of Health (NIH) to improve the collection of data on adolescent transition in Malawi, South Africa, and Thailand.

In 2016, three TREAT Asia investigators, Drs. Tavitiya Sudjaritruk, Suvaport Anugulruengkitt, and Watsamon Jantarabenjakul, were awarded prestigious grants under the CIPHER initiative to research medical problems experienced by HIV-positive youth. In addition, Dr. Nadia Kancheva-Landolt of HIV-NAT at the TRC-ARC conducted several studies aimed at improving the reproductive health of HIV-positive young women in Thailand, with funding from ViiV Healthcare. TREAT Asia has also been following 248 HIV-infected adolescents at nine sites in Malaysia, Thailand, and



The Thai Red Cross AIDS Research Centre's Drs. Nittaya Phanuphak and Praphan Phanuphak at the launch of the Adam's Love Clinic in Bangkok

Vietnam to evaluate social, cultural, and behavioral factors that affect treatment adherence. The study, which is being funded by LIFE+, uses an audio computer-assisted self-interview instrument.

### Expanding Pre-Exposure Prophylaxis (PrEP) in Thailand

In 2016, amfAR funded a study to assess combination HIV prevention needs, including pre-exposure prophylaxis (PrEP) among female sex workers in Bangkok and Pattaya, Thailand. The research team brings together experts from the Service Workers in Group (SWING) Foundation, a Thai advocacy organization for sex workers; Institute for Population and Social Research at Mahidol University in Bangkok; Johns Hopkins Bloomberg School of Public Health; and amfAR.

### Addressing Unmet Needs in HIV Care

In January 2016, TREAT Asia embarked on a think tank project to identify and address gaps in the management of HIV in Asia. The project includes over 20 experts in HIV and other sub-specialties from a dozen countries in the region. The think tanks are focusing on three priority areas: HIV and cardiovascular disease, HIV and liver disease, and HIV and drug resistance.

### Mobilizing HIV-Positive Youth

In February and May 2016, TREAT Asia held two Youth ACATA (Asia Community for AIDS Treatment and Advocacy) workshops in Bangkok for young people living with HIV from Cambodia, Indonesia, and Thailand. Launched in 2015 with support from ViiV Healthcare's Positive Action for Adolescents program, Youth ACATA aims to educate participants about HIV and antiretroviral therapy and connect them to other HIV-positive youth in the region.

### Promoting Treatment Access for GMT

In late 2015, with partial funding from amfAR, the Thai Red Cross AIDS Research Centre launched the Adam's Love Clinic for gay men, other men who have sex with men, and transgender individuals (collectively, GMT), as well as the Tangerine Community Health Centre—Southeast Asia's first transgender-specific sexual health clinic—both in Bangkok.

### Taking on Hepatitis C Co-Infection

In May 2016, TREAT Asia co-sponsored a training session in Bangkok for clinicians on treating hepatitis C and HIV co-infection with direct-acting antivirals. TREAT Asia conducted the training in collaboration with the International Network for Hepatitis in Substance Users and the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine. In August 2016, TREAT Asia hosted its fourth regional strategic meeting on hepatitis C virus treatment access with 22 participants from key population regional networks in eight Asian countries.

### Public Policy

Informed by thorough research and analysis, amfAR is a highly respected advocate of rational and compassionate AIDS-related public policy. Through its Public Policy Office in Washington, DC, amfAR educates policymakers, the media, and the public about evidence-based policies to address HIV/AIDS in the U.S. and around the world.

### Shaping the Domestic Response to HIV/AIDS

In February 2016, amfAR published an infographic titled *Small Increase, Big Impact*, illustrating the declining purchasing power of the National Institutes of Health's (NIH) HIV/AIDS research dollars. In 2016, the NIH budget was increased by \$2 billion, and President Obama proposed a further increase of \$825 million for 2017. However, HIV research funding remained at 2015 levels. An increase in HIV research funding in line with the increase in total NIH funding would have meant an additional \$76.6 million for HIV research for 2017. Such an increase would have allowed the NIH to fund 180 HIV/AIDS studies that could significantly advance HIV prevention, treatment, or cure research; 51 clinical trials focused on curing HIV; or a breakthrough prevention trial.



amfAR's Christina Chandra, Jack MacAllister, and Jennifer Sherwood pose with the Public Policy Office's posters and publications at the 2016 International AIDS Conference in Durban, South Africa.

### Key Populations

amfAR is dedicated to addressing the needs of the people most vulnerable to HIV infection: men who have sex with men, sex workers, people who inject drugs, and transgender individuals. In October 2015, amfAR published *Towards Defining an HIV Implementation Science Agenda for Key Populations in Low- and Middle-Income Countries* based on a meeting the Foundation hosted in May 2015 to brainstorm how implementation science

research might improve HIV outcomes for key populations in resource-limited settings. amfAR published *Following the Money to Key Populations, National Priorities, and Evidence-Based Budgeting* in June 2016. This report is a qualitative assessment of how Kenya and South Africa use health data for budgetary resource allocation.

In July 2016, amfAR published *Is PEPFAR Funding for Key Populations Aligned with the Epidemiologic Burden?* This report is based on an evaluation of the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). Worldwide, 40–50% of all HIV infections in adults aged 15–49 occur among key populations. The report concluded that the disproportionate HIV risk, along with poor quality health services, underscores the continuing importance of prioritizing resources and targeted interventions.

## Global Health

In FY2016, amfAR published *The World Without PEPFAR*, an infographic highlighting significant advances in global HIV/AIDS treatment and prevention made possible by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). Launched in 2003, PEPFAR made billions of dollars available for HIV programs in developing countries and fundamentally changed the course of the global epidemic.

amfAR also added new features and data to its PEPFAR Country/Regional Operational Plan database, a comprehensive, navigable database of PEPFAR's planned funding of HIV/AIDS activities from 2007 to 2015. Launched in 2015, the database is designed to help civil society organizations, ministries of health and finance, researchers, and other stakeholders access and understand PEPFAR's programs and priorities on a deeper level than was possible using other platforms.

## The GMT Initiative

Since 2007, amfAR has been serving the HIV-related needs of gay men, other men who have sex with men, and transgender individuals (collectively, GMT) throughout the developing world through its GMT Initiative. Through small, targeted grants to grassroots groups, amfAR has expanded access to HIV education and prevention services; supported advocacy aimed at increasing funding for prevention and treatment services; and worked to end the stigma, discrimination, and violence that threaten the lives of GMT and fuel the spread of HIV/AIDS.

## Implementation Science Awards

In FY2016, amfAR's grant making through the GMT Initiative evolved to support larger implementation science projects aimed at identifying barriers to HIV testing, treatment, and care and studying the impact of innovative HIV service delivery models for GMT in low- and middle-income countries. amfAR has awarded \$2.6 million over three years to support three such studies.

- ▶ Dr. Chris Beyrer of Johns Hopkins University is leading a team of researchers and community-based services (in collaboration with the International HIV/AIDS Alliance Myanmar) in evaluating the effectiveness of promising interventions for GMT in Myanmar, where increased HIV testing and treatment opportunities are becoming available. The researchers are assessing the



Kaung Htet Thu of the International HIV/AIDS Alliance Myanmar

effectiveness of HIV self-testing done in the privacy of one's home, point-of-care CD4 testing, and the use of "peer navigators" familiar with the local health system to help those newly diagnosed gain access to HIV treatment and care.

- ▶ In Lima, Peru, Dr. Javier Lama of Asociación Civil Impacta Salud y Educación and his team are aiming to improve the continuum of care among transgender women by using an innovative model that integrates HIV prevention and treatment services with transgender-affirming medical care.
- ▶ And in Bangkok, Dr. Nittaya Phanuphak and her team at the Thai Red Cross AIDS Research Centre are working to show how innovative technologies such as GMT-targeted websites that incorporate online counseling and support can be utilized to increase rates of HIV testing and referrals to prevention and treatment programs.

## amfAR HIV Scholars Program

In FY2016, amfAR supported four young researchers from Paraguay, Brazil, South Africa, and Indonesia undergoing five months of graduate-level public health study at the Center for LGBT Health Research at the University of Pittsburgh Graduate School of Public Health as part of the amfAR HIV Scholars Program. The program aims to strengthen GMT community-based research and responses to HIV, often in areas where little data about HIV among GMT currently exist and where stigma and discrimination deter many from seeking HIV testing and services. The 2016 amfAR HIV Scholars are Dr. Antonio Spagnolo of the National University of Asunción in Paraguay; Daniel Dutra de Barros of Santa Casa de São Paulo School of Medical Sciences in Brazil; Kabelo Maleke of Project Boithato at the Anova Health Institute in rural South Africa; and Adi Nugroho of the GWL-INA Network in Jakarta, Indonesia.

## Public Information

amfAR seeks to translate and disseminate information on important HIV/AIDS-related research, treatment, prevention, and policy issues for diverse audiences and to increase broad awareness and knowledge of the pandemic. amfAR also publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policymakers in communicating the need for continued research to develop new methods of prevention, treatment, and, ultimately, a cure for HIV.

## Educational Materials

amfAR produces a range of periodicals in both print and electronic formats, including its newsletter *Innovations*, published twice a year and distributed to more than 45,000 people; the *TREAT Asia Report*, an email newsletter distributed six times a year to more than 4,000 readers in the international health community; and a monthly e-mail newsletter distributed to nearly 100,000 people. The Foundation's website, which attracts an average of 40,000 visitors per month, features news, interviews, and original articles covering HIV/AIDS research, policy, the global epidemic, and amfAR programs and activities. amfAR also creates and distributes program reports, press releases, and updates on major HIV/AIDS issues, and conducts public service advertising campaigns that have been instrumental in educating policymakers, healthcare professionals, people living with HIV/AIDS, and the general public.

## Social Media

amfAR has vigorously expanded its presence in the social media arena, reaching large numbers of people, including a younger demographic that is often less educated about HIV and the AIDS epidemic. The Foundation regularly adds content to its Facebook page, live tweets from events, and posts images on Instagram from fundraising and program events. amfAR has 72,000 likes on Facebook, 40,000 Twitter followers, and more than 108,000 Instagram followers.

## Media Outreach

In 2016, amfAR continued to work closely with the media to raise the profile of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of HIV/AIDS-related press coverage. Articles and reports involving amfAR—many of which included interviews with amfAR staff and spokespeople—were carried in numerous media outlets, including *The New York Times*, *Forbes*, *The Advocate*, the *South China Morning Post*, CBS Radio, Reuters, and Bloomberg News.

## Enlisting the Help of Public Figures

amfAR's public awareness efforts are greatly enhanced by the committed support of public figures who lend their voices and donate their time, talents, and resources to help sustain the Foundation's mission. Support of amfAR by prominent public figures began with the late Dame Elizabeth Taylor, amfAR's Founding International Chairman, and others have followed in her footsteps. amfAR is profoundly grateful for the continuing steadfast support of Global Campaign Chair Sharon Stone.

Other celebrity supporters included amfAR Ambassadors Milla Jovovich, Michelle Yeoh, and Cheyenne Jackson, Kathy Bates, Angela Bassett, Julia Roberts, Matt Bomer, Jamie Lee Curtis, Diane von Furstenberg, Gwyneth Paltrow, Chiara Ferragni, Ryan Murphy, Lady Gaga, Diane Kruger, Uma Thurman, Dame Helen Mirren, Faye Dunaway, Katy Perry, Kate Moss, Marc Jacobs, Ricky Martin, Lea Michele, Michelle Rodriguez, Whoopi Goldberg, amfAR Trustee Harry Belafonte, Naomi Campbell, Heidi Klum, Riccardo Tisci, Adrien Brody, Eva Longoria, Harvey Keitel, Leonardo DiCaprio, Robert De Niro, Robin Thicke, Andrea Bocelli, Dean and Dan Caten, Chris Tucker, Jennifer Garner, Donatella Versace, and Carine Roitfeld.

In 2016, a collection of 1980s classic hits was updated by contemporary artists for *The Time is Now!*—a 14-track compilation album to benefit amfAR. The album features a soulful rendition of Michael Jackson's "Billie Jean" by singer-songwriter Aloe Blacc, and a rendition of New Order's "Bizarre Love Triangle" performed by Sugar for Sugar, consisting of Scarlett Johansson, Julia Haltigan, Holly Miranda, and Kendra Morris. The band Lower Dens, pop rock group DNCE, Dita Von Teese and Sebastien Tellier, and songwriting duo Marian Hill are also featured on the album.

The collage features several key documents:

- Following the Money to Key Populations, National Priorities, and Evidence-Based Budgeting**: A report with a red header and a line graph showing funding trends.
- Is PEPFAR Funding for Key Populations Aligned with the Epidemiologic Burden?**: A blue header report with a world map.
- Lifting All Boats: The Broad Benefits of Increased Investments in HIV/AIDS Research**: A report with a blue header and a line graph showing research funding from 2002 to 2017.
- TREAT ASIA**: A yellow header report titled "Hepatitis C Treatment Snapshots: Ledipasvir + Sofosbuvir".
- amfAR INNOVATIONS**: A blue header newsletter titled "Harnessing the Power of Antibodies" with the subtext "Could they hold the key to an HIV cure?".
- The Broad Benefits of AIDS Research**: A blue header report.
- Fact Sheet on WHO Guidelines for the Screening, Care, and Treatment of Persons with Hepatitis C Infection**: A blue header fact sheet with icons and text.
- The World Without PEPFAR**: A white header report with a red header and various statistics and icons.



## 2016 RESEARCH GRANTS, FELLOWSHIPS, AND AWARDS

All projects listed below were awarded funding during the period October 1, 2015, through September 30, 2016.

<sup>1</sup>Supported in part with funds provided by the FAIR Foundation

### amfAR INSTITUTE FOR HIV CURE RESEARCH

Principal Investigator:  
Paul Volberding, MD  
University of California, San Francisco  
San Francisco, CA  
\$20,000,000

### amfAR RESEARCH CONSORTIUM ON HIV ERADICATION (ARCHE)

**Predictors of time to viremia with an analytic treatment interruption**  
Principal Investigator:  
Timothy Schacker, MD  
University of Minnesota  
Minneapolis, MN  
\$671,846

**Allogeneic stem cell transplant in HIV-1-Infected Individuals**  
Principal Investigator:  
Annemarie Wensing, MD, PhD  
University Medical Center Utrecht  
Utrecht, The Netherlands  
\$849,910

**Development of a humanized superagonist antibody to human IL-21 for HIV cure**  
Principal Investigator:  
Di Yu, PhD  
Monash University  
Clayton, Australia  
\$225,512

### INVESTMENT GRANTS

**Eradicating the HIV reservoir: Using microfluidics to exploit killer T cells**  
Principal Investigator:  
David Weitz, PhD  
Harvard University  
Cambridge, MA  
\$977,114

**Tandem latency reversal and suicide prodrugs to eliminate HIV reservoirs**  
Principal Investigator:  
Alexander Zelikin, PhD  
Aarhus University  
Aarhus, Denmark  
\$962,510

### INNOVATION GRANTS

**Analytic treatment interruption to study viral reservoirs and as test for cure in HIV-infected adults on ART**  
Principal Investigator:  
Steven Deeks, MD  
University of California, San Francisco  
San Francisco, CA  
\$77,764

**Uncovering HIV-1-infected cells: a new path towards a cure**  
Principal Investigator:  
Andrés Finzi, PhD  
Université de Montréal, Centre de Recherche du CHUM  
Montreal, Canada  
\$199,997<sup>1</sup>

**Hormonal control of latent HIV proviruses**  
Principal Investigator:  
Jonathan Karn, PhD  
Case Western Reserve University  
Cleveland, OH  
\$200,000<sup>1</sup>

**Quantitative HIV reservoir assay using bar-coded RNA**  
Principal Investigator: Jonathan Karn, PhD  
Case Western Reserve University  
Cleveland, OH  
\$200,000<sup>1</sup>

**Optimized assays to measure the latent SIV reservoir in rhesus macaques on ART**  
Principal Investigator:  
Maud Mavigner, PhD  
Emory University  
Atlanta, GA  
\$200,000<sup>1</sup>

**Mechanisms and correlates of post-ART treatment control in SIV-infected macaques**  
Principal Investigator:  
Mirko Paiardini, PhD  
Emory University  
Atlanta, GA  
\$200,000<sup>1</sup>

**Genomic locations of HIV proviruses responsive to latency reversing agents**  
Principal Investigator:  
Celsa Spina, PhD  
University of California, San Diego  
San Diego, CA  
\$200,000<sup>1</sup>

**Discovery of tools to modify the fate of uracilated HIV DNA in macrophages**  
Principal Investigator:  
James Stivers, PhD  
Johns Hopkins University  
Baltimore, MD  
\$200,000<sup>1</sup>

### MATHILDE KRIM FELLOWSHIPS IN BASIC BIOMEDICAL RESEARCH

**HIV cell-to-cell transmission and the establishment of latency**  
Principal Investigator:  
Luis Agosto, PhD  
Boston Medical Center  
Boston, MA  
\$150,000

**Rational immunogen design based on study of potent HIV-1 trimer-specific bNAbs**  
Principal Investigator:  
Louise Scharf, PhD  
California Institute of Technology  
Pasadena, CA  
\$150,000

**Identification, reactivation and elimination of latent HIV-1 in humanized mice**  
Principal Investigator:  
Liang Shan, PhD  
Yale University  
New Haven, CT  
\$150,000

**Determinants of HIV-1 replication in non-human primate models**  
Principal Investigator:  
Amit Sharma, PhD  
Fred Hutchinson Cancer Research Center  
Seattle, WA  
\$146,829

### PHASE II KRIM FELLOWSHIP GRANTS

**Optimization of anti-HIV antibodies for prevention and therapy**  
Principal Investigator:  
Stylianos Bournazos, PhD  
The Rockefeller University  
New York, NY  
\$80,000

**Identification of transmitted viral determinants of HIV pathogenesis**  
Principal Investigator:  
Dario DiLernia, PhD  
Emory University  
Atlanta, GA  
\$50,000

**Identification of a novel HIV-1 restriction factor induced by RNA sensing**  
Principal Investigator:  
Henning Hofmann, PhD  
Robert Koch Institute  
Berlin, Germany  
\$80,000

**Targeting engineered nanoparticles for therapeutic purge of HIV-1 reservoir**  
Principal Investigator:  
Nuria Izquierdo-Useros, PhD  
Fundación IrsiCaixa  
Barcelona, Spain  
\$50,000

### SCIENTIFIC MEETINGS

**Conference on Cell & Gene Therapy for HIV Cure (2016)**  
Principal Investigator:  
Keith Jerome, MD, PhD  
Fred Hutchinson Cancer Research Center  
Seattle, WA  
\$10,000

**International AIDS Conference 2016**  
Principal Investigator:  
Owen Ryan, MPH, MIA  
International AIDS Society  
Geneva, Switzerland  
\$50,000

## 2016 TREAT ASIA GRANTS AND AWARDS

All projects listed below were awarded funding during the period October 1, 2015, through September 30, 2016.

<sup>1</sup>Supported by National Institutes of Health cooperative agreement number U01AI069907 with funds from the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute of Mental Health, and the National Institute on Drug Abuse

<sup>2</sup>Supported by National Institutes of Health grant number R01HD073972 funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development

<sup>3</sup>Supported with funds provided by the AIDS Life Association

<sup>4</sup>Supported with funds provided by the Open Society Foundations

<sup>5</sup>Supported with funds provided by Viiv Healthcare

### AUSTRALIA

#### AUSTRALIA HIV OBSERVATIONAL DATABASE (AHOD) SITES

**O'Brien Street Practice**  
Adelaide, South Australia  
William Donohue, MBBS  
\$1,575

**Sexual Health and HIV Service In Metro North**  
Brisbane, Queensland  
Diane Rowling, MBBS, RACP, FACHSHM  
\$3,600<sup>1</sup>

**Cairns Sexual Health Service**  
Cairns, Queensland  
Darren Russell, MD  
\$5,250<sup>1</sup>

**RPA Sexual Health Clinic**  
Camperdown, New South Wales  
David Templeton, MBChB, PhD  
\$675

**Monash Health - Clayton**  
Clayton, Victoria  
Ian Woolley, MBBS, FRACP  
\$5,475

**D.A. Ellis Pty., Ltd.**  
Coffs Harbour, New South Wales  
David Ellis, MBBS  
\$675

**East Sydney Doctors**  
Darlinghurst, New South Wales  
David Baker, MB, ChB, Dip Med, DCH  
\$7,050<sup>1</sup>

**Holdsworth House Medical Practice**  
Darlinghurst, New South Wales  
Mark Bloch, MD  
\$5,925<sup>1</sup>

**St. Vincent's Hospital Sydney**  
Darlinghurst, New South Wales  
David A. Cooper, MD  
\$5,475<sup>1</sup>

**Taylor Square Private Clinic**  
Darlinghurst, New South Wales  
Robert Finlayson, MBBS, DipVen, FACHSHM  
\$5,025<sup>1</sup>

**Northern Territory Dept of Health & Community Services, Sexual Health & Blood Borne Virus Program**  
Darwin, Northern Territory  
Manoji Gunathilake, MD, MBBS, FACHSHM  
\$975

**Gladstone Road Medical Centre**  
Highgate Hill, Queensland  
David Orth, MBBS, DipVen  
\$5,100<sup>1</sup>

**Nepean Blue Mountains Local Health District, Blue Mountains Sexual Health and HIV Clinic**  
Katoomba, New South Wales  
Eva Jackson, MBBS, FACHSHM  
\$1,575

**Nepean Blue Mountains Local Health District, Nepean Sexual Health Clinic**  
Kingswood, New South Wales  
Julian Langton-Lockton, MBBS  
\$1,350

**Sexual Health and AIDS Services (SHAIDS)**  
Lismore, New South Wales  
David Smith, MBBS, DipVen, FACHSHM, GrapDip BA  
\$6,075<sup>1</sup>

**Melbourne Sexual Health Centre**  
Clayton, Victoria  
Tim Read, MBBS, DipVen, FRACGP, FACHSHM, EpiDip  
\$4,425<sup>1</sup>

**Victorian HIV Service, Infectious Diseases Department, The Alfred Hospital**  
Melbourne, Victoria  
Jennifer Hoy, MBBS  
\$5,550<sup>1</sup>

**Sunshine Coast Hospital and Health Service**  
Nambour West, Queensland  
David Sowden, MBBS  
\$6,375<sup>1</sup>

**Northside Clinic (Vic) Pty Ltd**  
North Fitzroy, Victoria  
Richard Moore, MBBS  
\$7,500<sup>1</sup>

**Royal Perth Hospital**  
Perth, Western Australia  
David Nolan, MBBS, FRACP, PhD  
\$5,175<sup>1</sup>

**Prahran Market Clinic Pty., Ltd.**  
Prahran, Victoria  
Norman Roth, MBBS FACHSHM  
\$5,775<sup>1</sup>

**Sydney Sexual Health Centre, Sydney Hospital**  
Sydney, New South Wales  
Caroline Thng, MBBS, MRCP  
\$4,275<sup>1</sup>

**Clinic 468, HNE Sexual Health, Hunter New England Local Health District**  
Tamworth NEMSC, New South Wales  
Nathan Ryder, MD  
\$900

**Illawarra Shoalhaven Local Health District**  
Warrawong, New South Wales  
Katherine Brown, MD  
\$1,350

**UNSW-Sydney**  
Sydney, New South Wales  
Matthew G. Law, PhD  
IeDEA Asia-Pacific Research Collaboration: TREAT Asia HIV Observational Database & Australia HIV Observational Database  
\$256,385<sup>1</sup>

IeDEA Asia-Pacific Research Collaboration: HIV and aging in TAHOD-LITE  
\$15,000<sup>1</sup>

IeDEA Asia-Pacific Research Collaboration: Cancer Studies  
\$135,922<sup>1</sup>

IeDEA Asia-Pacific Research Collaboration: TREAT Asia Pediatric HIV Observational Database  
\$175,225<sup>1</sup>

Effectiveness and tolerability of hepatitis C treatment in HIV co-infected patients in routine care services in Asia  
\$19,289

### CAMBODIA

**National Center for HIV/AIDS, Dermatology & STDS / Cambodia National Institute of Public Health**  
Phnom Penh  
Ly Penh Sun, MD, MSc  
TREAT Asia HIV Observational Database (TAHOD)  
\$20,000<sup>1</sup>

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2)  
\$33,666<sup>5</sup>

TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$25,000<sup>3</sup>

**New Hope for Cambodian Children**  
Killeen, TX  
John Tucker  
Our Village  
\$20,743<sup>3</sup>

Our Village and New Hope House  
\$50,000

### CHINA

**Beijing Ditan Hospital**  
Beijing  
Fujie Zhang, MD, MSPH, PhD  
TREAT Asia HIV Observational Database (TAHOD)  
\$16,000<sup>1</sup>

**Queen Elizabeth Hospital**  
Hong Kong  
Man Po Lee, MBBS  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$23,030<sup>1</sup>

## INDIA

### Johns Hopkins University at B.J. Medical College and Sassoon General Hospital Pune

Vidya Mave, MD, MPH  
Epidemiology of HIV/AIDS and associated comorbidities in a public antiretroviral treatment (ART) clinic in Pune, India  
\$150,000<sup>1</sup>

### Chennai Antiviral Research and Treatment Clinical Research Site, YRG CARE Medical Centre, VHS Chennai

Nagalingeswaran Kumarasamy, MBBS, PhD  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$22,040<sup>1</sup>

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2)  
\$5,000<sup>5</sup>

TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$7,500<sup>3</sup>

### Institute of Infectious Diseases

Pune  
Sanjay Pujari, MD, AAHIVS, MBBS  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$22,410<sup>1</sup>

### Wide Angle Social Development Organization

Imphal  
Rajkumar Nalinikanta  
Improving HBV & HCV prevention & treatment access in Manipur-Phase IV  
\$10,060

## INDONESIA

### Cipto Mangunkusumo General Hospital

Jakarta  
Nia Kurniati, MD  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$7,500<sup>3</sup>

Evy Yunihastuti, MD, PhD  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$22,900<sup>1</sup>

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2)  
\$35,156<sup>5</sup>

Effectiveness and tolerability of HCV treatment in HIV co-infected patients: Treatment  
\$11,603

### Indonesia AIDS Coalition

Jakarta  
Aditya Wardhana  
Hep C – Know it, get tested and beat it!  
\$6,583<sup>4</sup>

### Sanglah Hospital, Udayana University School of Medicine

Denpasar, Bali  
Tuti Parwati Merati, MD, PhD  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$22,440<sup>1</sup>

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2)  
\$28,264<sup>5</sup>

Ketut Dewi Kumara Wati, MD  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$7,500<sup>3</sup>

### Persaudaraan Korban Napza Indonesia (PKNI)

Jakarta  
Edo Agustian  
Increasing awareness of hepatitis C with 360 short movie campaign  
\$2,500<sup>4</sup>

## JAPAN

### National Center for Global Health and Medicine

Tokyo  
Junko Tanuma, MD, PhD  
TREAT Asia HIV Observational Database (TAHOD)  
\$16,000<sup>1</sup>

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2)  
\$2,000<sup>5</sup>

## MALAYSIA

### Hospital Likas

Kota Kinabalu  
Fong Siew Moy, MBBS  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$7,500<sup>3</sup>

### Hospital Raja Perempuan Zainab II

Kota Bharu  
Nik Khairulddin Nik Yusoff, MBBS  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$7,500<sup>3</sup>

### Pediatric Institute, Hospital Kuala Lumpur

Kuala Lumpur  
Thahira A. Jamal Mohamed, MBBS  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$7,500<sup>3</sup>

### Penang Hospital

Georgetown  
Revathy Nallusamy, MBBS  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$2,500<sup>3</sup>

### Sungai Buloh Hospital

Sungai Buloh  
Yasmin Mohamed Gani, MD  
Study of Transitioning Asian Youth (STAY) Cohort  
\$14,561<sup>5</sup>

Benedict Lim Heng Sim, MBBS, MRCP  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$16,130<sup>1</sup>

### University of Malaya

Kuala Lumpur  
Raja Iskandar Shah Raja Azwa, MBBS  
Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2)  
\$45,361<sup>5</sup>

Adeeba Kamarulzaman, MBBS, FRACP, FAMB, FASc  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$22,390<sup>1</sup>

Effectiveness and tolerability of HCV treatment in HIV co-infected patients: Treatment  
\$7,581

## NEPAL

### Union C

Kathmandu  
Roshan Sapkota  
National Awareness Campaign-NEPAL  
\$7,001

## PHILIPPINES

### Research Institute for Tropical Medicine

Muntinlupa City  
Rossana Ditungco, MD  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$22,640<sup>1</sup>

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2)  
\$5,950<sup>5</sup>

## SINGAPORE

### Tan Tock Seng Hospital

Singapore  
Oon Tek Ng, MBBS  
TREAT Asia HIV Observational Database (TAHOD)  
\$19,250<sup>1</sup>

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2)  
\$2,000<sup>5</sup>

## SOUTH KOREA

### Yonsei University College of Medicine

Seoul  
Jun Yong Choi, MD, PhD  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$18,290<sup>1</sup>

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2)  
\$2,000<sup>5</sup>

## TAIWAN

### Taipei Veterans General Hospital

Taipei City  
Wing-Wai Wong, MD  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$23,670<sup>1</sup>

## THAILAND

### Chiang Mai University – Research Institute for Health Sciences

Chiang Mai  
Linda Aurpibul, MD  
Long-term HBV treatment outcome in HIV-HBV co-infected adolescents receiving tenofovir-containing ARV regimen  
\$5,230<sup>5</sup>

Romane Chaiwarith, MD, MHS  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$23,990<sup>1</sup>

Tavitiya Sudjaritruk, MD, ScM, PhD  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$15,000<sup>3</sup>

Peripheral Arterial Diseases among Perinatally HIV-infected Thai Adolescents (PAD study)  
\$18,423<sup>1</sup>

#### **Chiangrai Prachanukroh Hospital**

Chiang Rai  
Rawiwan Hansudewechakul, MD  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$15,000<sup>3</sup>

Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia  
\$64,043<sup>2</sup>

Study of Transitioning Asian Youth (STAY) Cohort  
\$21,690<sup>3</sup>

Pacharee Kantipong, MD  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$30,040<sup>1</sup>

#### **HIV-NAT / Thai Red Cross AIDS Research Centre**

Bangkok  
Praphan Phanuphak, MD, PhD  
Examining the prevalence rate and determinants of frailty in the HIV positive and negative Thai populations  
\$2,545<sup>1</sup>

Anchalee Avihingsanon, MD, PhD  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$22,280<sup>1</sup>

Sivaporn Gatechompol, MD  
Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia  
\$65,687<sup>2</sup>

Watsamon Jantarabenjakul, MD  
Treatment switch from efavirenz to rilpivirine in virologically-suppressed HIV-infected Thai adolescents  
\$4,974

Stephen Kerr, PhD  
Understanding adherence, stigma, and behavioral risk factors of adolescents in TApHOD using ACASI (data management center)  
\$9,000<sup>1</sup>

Study of Transitioning Asian Youth (STAY) Cohort Statistical Analysis Center  
\$18,038<sup>1</sup>

Nittaya Phanuphak, MD, PhD  
Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia (central lab and data manager)  
\$223,151<sup>2</sup>

Neovaginal and anal HPV and related diseases among post-operative transgender women  
\$35,455<sup>1</sup>

Wasana Prasitsuebsai, MD, MPH  
Coordinating Center: Prospective Monitoring of Second-line Antiretroviral Therapy Failure and Resistance in Children  
\$32,075<sup>5</sup>

Thanyawee Puthanakit, MD  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$15,000<sup>3</sup>

Peripheral Arterial Diseases among Perinatally HIV-infected Thai Adolescents  
\$13,402<sup>1</sup>

Kiat Ruxrungtham, MD  
Effectiveness and tolerability of HCV treatment in HIV co-infected patients: Treatment  
\$11,421

#### **Thai Red Cross AIDS Research Centre**

Bangkok  
Tarandee Anand  
The impact of online interventions on the HIV prevention/treatment cascade among MSM and transgender individuals  
\$21,600

Thanyawee Puthanakit, MD  
Supporting HIV-infected Adolescents and Youth in Achieving Successful Transition to Adult Care  
\$30,000<sup>3</sup>

#### **Mahidol University by Faculty of Medicine Siriraj Hospital**

Kulkanya Chokephaibulkit, MD  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$15,000<sup>3</sup>

Understanding adherence, stigma, and behavioral risk factors of adolescents in TApHOD using ACASI  
\$2,765<sup>1</sup>

Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia  
\$49,839<sup>2</sup>

Study of Transitioning Asian Youth (STAY) Cohort  
\$24,958<sup>1</sup>

Treatment switch from efavirenz to rilpivirine in virologically-suppressed HIV-infected Thai adolescents  
\$14,996

**Ramathibodi Hospital, Mahidol University**  
Sasisopin Kiertiburanakul, MD, MHS  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$23,150<sup>1</sup>

**Srinagarind Hospital, Khon Kaen University**  
Khon Kaen  
Pope Kosalaraksa  
Treatment switch from efavirenz to rilpivirine in virologically-suppressed HIV-infected Thai adolescents  
\$12,621

Pagakrong Lumbiganon, MD  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$8,100<sup>3</sup>

Study of Transitioning Asian Youth (STAY) Cohort  
\$21,251<sup>5</sup>

## **USA**

#### **Massachusetts General Hospital**

Boston, MA  
Andrea Ciaranello, MD, MPH  
Estimating the magnitude of the pediatric and adolescent HIV epidemic in Thailand  
\$59,951

## **VIETNAM**

#### **Bach Mai Hospital**

Hanoi  
Do Duy Cuong, MD, PhD  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$22,720<sup>1</sup>

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2)  
\$11,978<sup>5</sup>

#### **Children's Hospital 1**

Ho Chi Minh City  
Tran Ngoc Hanh Dan, MD, MSc

Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia  
\$8,777<sup>2</sup>

Truong Huu Khanh, MD  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$25,000<sup>3</sup>

Understanding adherence, stigma, and behavioral risk factors of adolescents in TApHOD using ACASI  
\$4,736<sup>1,3</sup>

#### **Children's Hospital 2**

Ho Chi Minh City  
Do Chau Viet, MD  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$20,000<sup>3</sup>

#### **Hung Vuong Hospital**

Ho Chi Minh City  
Dang Le Dung Hanh, MD, MA  
Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia  
\$13,337<sup>2</sup>

#### **National Hospital of Pediatrics**

Hanoi  
Nguyen Van Lam, MD, MSc  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$20,000<sup>3</sup>

Study of Transitioning Asian Youth (STAY) Cohort  
\$8,791<sup>5</sup>

#### **National Hospital of Tropical Diseases**

Hanoi  
Nguyen Van Kinh, MD, PhD  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$22,610<sup>1</sup>

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2)  
\$26,568<sup>5</sup>

Effectiveness and tolerability of HCV treatment in HIV co-infected patients: Treatment  
\$9,023

#### **Vietnam Network of People Living with HIV (VNP+)**

Hanoi  
Do Dang Dong  
Increase knowledge about HCV diagnosis, and care and treatment access in the PLHIV and PWID community  
\$6,500<sup>4</sup>

## 2016 GMT INITIATIVE GRANTS AND AWARDS

All projects listed below were awarded amfAR funding for the period October 1, 2015, through September 30, 2016.

### AMFAR HIV SCHOLARS AWARDS

#### Designing trans-community led HIV treatment counseling programs suitable for the needs of trans populations in South Africa

Principal Investigator: Liesl Theron  
Gender DynamiX  
Cape Town, South Africa  
\$25,000

#### Pilot study on HIV among men who have sex with men in Belize

Principal Investigator: Erika Castellanos  
Collaborative Network of Persons Living with HIV (C-NET+)  
Belize City, Belize  
\$25,000

#### Assessing the efficacy of online HIV home testing support service to increase quarterly HIV testing among MSM

Principal Investigator: Weibin Cheng  
GZTZ.ORG  
Guangzhou, China  
\$25,000

#### Identifying barriers in accessing care services for low-adherence to ART by MSM and transgender populations in Pakistan

Principal Investigator: Sheryar Kazi  
NAZ Male Health Alliance  
Lahore, Pakistan  
\$25,000

### GENERAL GMT INITIATIVE GRANTS AND AWARDS

#### A training program for HIV research among MSM in low- and middle-income countries

Project Director: Ronald D. Stall, PhD, MPH  
University of Pittsburgh  
Pittsburgh, PA  
\$164,000

## 2016 PUBLIC POLICY AWARDS

The projects listed below were awarded amfAR funding during the period October 1, 2015, through September 30, 2016.

### UNITED STATES

#### Evaluation of needle exchange distribution policy

Project Director: Susan Sherman, PhD  
Johns Hopkins University  
Baltimore, MD  
\$60,000

#### Improving the health of young black men who have sex with men (MSM)

Project Director: Jeffrey Crowley  
Georgetown University  
Washington, DC  
\$99,350

#### PrEP advocacy and demand creation for MSM

Project Director: Emily Bass  
AIDS Vaccine Advocacy Coalition (AVAC)  
New York, NY  
\$50,600

#### Developing local strategies to implement safe injection facilities (SIFs)

Project Director: Emily Mariko-Sanders  
Project Inform  
San Francisco, CA  
\$10,000

### INTERNATIONAL

#### Increasing access to services for PLHIV who use drugs in the Philippines

Project Director: Cara O'Connor  
Sustained Health Initiatives of the Philippines  
Mandaluyong City, Philippines  
\$30,000



## Financial Highlights




For the year ended September 30, 2016


<b>Public Support and Revenue</b>		
Public support	\$	7,104,647
Special events		22,840,383
Planned giving		4,995,589
Government funding		13,063,451
Investment income and other revenue		2,535,019
<b>Total public support and revenue</b>	<b>\$</b>	<b>50,539,089</b>
<hr/>		
<b>Expenses</b>		
Research	\$	20,306,002
TREAT Asia		5,276,103
GMT Initiative		1,737,688
Public Policy		2,162,183
Public Information		3,892,270
<b>Total program services</b>	<b>\$</b>	<b>33,374,246</b>
<hr/>		
Fundraising		6,054,303
Management and general		2,509,982
<b>Total supporting services</b>	<b>\$</b>	<b>8,564,285</b>
<hr/>		
<b>Total expenses</b>	<b>\$</b>	<b>41,938,531</b>
<hr/>		
Change in net assets		8,600,558
Net assets, beginning of year		53,038,622
<b>Net assets, end of year</b>	<b>\$</b>	<b>61,639,180</b>

## Statement of Financial Position






<b>Assets</b>		
Cash and investments	\$	64,039,115
Pledges and receivables, net		10,460,976
Prepaid expenses and other assets		3,297,004
Furniture, equipment, and leasehold improvements, net		2,976,566
<b>Total Assets</b>	<b>\$</b>	<b>80,773,661</b>
<hr/>		
<b>Liabilities</b>		
Accounts payable and accrued expenses	\$	3,412,592
Grants and fellowships payable, net		2,973,966
Deferred support and refundable advances		10,727,662
Other long-term liabilities		2,020,261
<b>Total liabilities</b>	<b>\$</b>	<b>19,134,481</b>
<hr/>		
<b>Total net assets</b>		<b>61,639,180</b>
<hr/>		
<b>Total liabilities and net assets</b>	<b>\$</b>	<b>80,773,661</b>


## Expenses

	Fundraising	\$	6,054,303
	Management and general		2,509,982
	Program		33,374,246
<b>Total</b>		<b>\$</b>	<b>41,938,531</b>



## Program Expenses

	Research	\$	20,306,002
	TREAT Asia		5,276,103
	GMT Initiative		1,737,688
	Public Policy		2,162,183
	Public Information		3,892,270
<b>Total</b>		<b>\$</b>	<b>33,374,246</b>





## BOARD OF TRUSTEES

Fiscal year 2016

Chairman of the Board

**Kenneth Cole**

Chairman  
Kenneth Cole Productions  
New York, NY

Founding Chairman

**Mathilde Krim, Ph.D.**

Adjunct Professor  
Mailman School of Public Health  
Columbia University  
New York, NY

Vice Chairman

**Patricia J. Matson**

Senior Vice President, Communications (ret.)  
ABC, Inc.  
New York, NY

Vice Chairman and Treasurer

**John C. Simons**

Managing Partner  
Corporate Fuel Partners, LLC  
New York, NY

Secretary

**Mervyn F. Silverman, M.D., M.P.H.**

President  
Mervyn F. Silverman Associates  
Crockett, CA

### TRUSTEES

**Arlen H. Andelson**

Senior Partner (ret.)  
Andelson & Andelson  
Los Angeles, CA

**Harry Belafonte**

President  
Belafonte Enterprises, Inc.  
New York, NY

**David Bohnett**

Chairman  
David Bohnett Foundation  
Beverly Hills, CA

**Zev Braun**

President and CEO  
Braun Entertainment Group, Inc.  
Beverly Hills, CA

**Jonathan S. Canno**

New York, NY

**Donald A. Capoccia**

Managing Principal  
BFC Partners  
Brooklyn, NY

**R. Martin Chavez, Ph.D.**

Chief Information Officer  
The Goldman Sachs Group, Inc.  
New York, NY

**Jane B. Eisner**

President  
The Eisner Foundation  
Bel Air, CA

**T. Ryan Greenawalt**

Managing Director  
Ramirez & Co.  
President  
Harrison Street Productions  
New York, NY

**Regan Hofmann**

Policy Officer  
U.S. Liaison Office  
UNAIDS  
Washington, D.C.

**Michael J. Klingensmith**

Publisher and CEO  
Star Tribune  
Minneapolis, MN

**Kevin McClatchy**

Chairman of the Board  
The McClatchy Company  
Ligonier, PA

**Michele V. McNeill, Pharm.D.**

Chairman  
McNeill Family Foundation  
Sarasota, FL

**Edward L. Milstein**

Co-Chairman, Milford Management  
Co-Chairman, Emigrant Savings Bank  
Partner, Milstein Properties  
New York, NY

**Cindy D. Rachofsky**

Philanthropist  
Dallas, TX

**Vincent A. Roberti**

Chairman, Roberti Global, LLC  
Managing Director, Roberti Associates Global, LLC  
Washington, D.C.

**Bill Roedy**

London, UK

**Raymond F. Schinazi, Ph.D., D.Sc.**

Frances Winship Walters Professor of Pediatrics  
Director, Laboratory of Biochemical Pharmacology  
Emory University  
Decatur, GA

**Alan D. Schwartz**

Executive Chairman  
Guggenheim Partners, LLC  
New York, NY

**Diana L. Taylor**

Vice Chair  
Solera Capital, LLC  
New York, NY

### TRUSTEE EMERITUS

**Arthur J. Ammann, M.D.**

President, Global Strategies for HIV Prevention  
Clinical Professor of Pediatrics  
University of California, San Francisco  
San Francisco, CA

### IN MEMORIAM

**Dame Elizabeth Taylor**

Founding International Chairman

**Sheldon W. Andelson, Esq.**

Arnold W. Klein, M.D.  
Mrs. Albert D. Lasker  
Jonathan M. Mann, M.D., M.P.H.  
Maxine Mesinger  
Pauline Phillips  
Natasha Richardson  
Allan Rosenfield, M.D.  
Peter Scott, Esq.  
Tom Stoddard  
Joel D. Weisman, D.O.

### SPECIAL APPOINTMENTS

Global Campaign Chair

Sharon Stone

Global Fundraising Chairman

Milutin Gatsby

### amfAR AMBASSADORS

Cheyenne Jackson

Janet Jackson

Milla Jovovich

Liza Minnelli

Michelle Yeoh

### COMMITTEES OF THE BOARD OF TRUSTEES

#### Executive

Kenneth Cole, Chair

Michael J. Klingensmith

Mathilde Krim, Ph.D.

Patricia J. Matson

Vincent A. Roberti

Mervyn F. Silverman, M.D., M.P.H.

John C. Simons

#### Audit

John Simons, Chair

R. Martin Chavez, Ph.D.

T. Ryan Greenawalt

#### Board Development

Donald A. Capoccia, Co-Chair

Patricia J. Matson, Co-Chair

Arlen Andelson

Bill Roedy

Mervyn F. Silverman, M.D., M.P.H.

#### Communications/Social Media/Marketing

Regan Hofmann, Chair

Kenneth Cole

T. Ryan Greenawalt

Patricia J. Matson

Kevin McClatchy

Vincent A. Roberti

Bill Roedy

#### Compensation and Organizational Development

John C. Simons, Chair

Michael J. Klingensmith

Kevin McClatchy

#### Finance & Budget

Michael J. Klingensmith, Chair  
Vincent A. Roberti  
John C. Simons

#### Fund Development

Vincent A. Roberti, Chair  
Arlen Andelson  
Jonathan S. Canno  
Donald A. Capoccia  
T. Ryan Greenawalt  
Cindy Rachofsky  
Raymond F. Schinazi, Ph.D., D.Sc.

#### Investment

Michael J. Klingensmith, Chair  
R. Martin Chavez, Ph.D.  
T. Ryan Greenawalt  
Edward L. Milstein  
Vincent A. Roberti  
John C. Simons

## SCIENTIFIC ADVISORY COMMITTEE

Daniel C. Douek, M.D., Ph.D. (Chair)  
Chief, Human Immunology Section  
Vaccine Research Center  
National Institute of Allergy and Infectious Diseases  
National Institutes of Health

Galit Alter, Ph.D.  
Associate Professor  
Department of Medicine  
Harvard Medical School

Deborah Anderson, Ph.D.  
Professor of Obstetrics/Gynecology  
and Microbiology  
Boston University School of Medicine

Jintanat Ananworanich, M.D., Ph.D.  
Associate Director for Therapeutics Research  
U.S. Military HIV Research Program

Warren A. Andiman, M.D.  
Professor Emeritus of Pediatrics  
Co-Director, Yale Adoption Clinic  
Medical Director, Pediatric AIDS Care Program  
Yale School of Medicine

Eric Arts, Ph.D.  
Professor  
Department of Microbiology and Immunology  
The University of Western Ontario

Livio Azzoni, Ph.D.  
Senior Staff Scientist  
The Wistar Institute  
Philadelphia, PA

Michael Betts, Ph.D.  
Associate Professor  
Department of Microbiology  
Perelman School of Medicine  
University of Pennsylvania

Jason Brenchley, Ph.D.  
Senior Investigator  
Immunopathogenesis Section  
National Institute of Allergy and Infectious Diseases  
National Institutes of Health

Dennis R. Burton, Ph.D.  
Professor  
Department of Immunology  
The Scripps Research Institute

Salvatore T. Butera, D.V.M., Ph.D.  
Chief Science Officer  
Scripps CHAVI-ID  
The Scripps Research Institute

Edward Campbell, Ph.D.  
Assistant Professor  
Department of Microbiology and Immunology  
School of Medicine  
Loyola University at Chicago

Alex Carballo-Dieguez, Ph.D.  
Co-Director and Senior Research Scientist  
HIV Center for Clinical and Behavioral Studies  
New York State Psychiatric Institute  
Columbia University

Nicolas Chomont, Ph.D.  
Assistant Professor  
Microbiology and Immunology  
Université de Montréal, Centre de Recherche du CHUM

David B. Clifford, M.D.  
Professor  
Department of Neurology  
Washington University School of Medicine

C. Budd Colby, Ph.D.  
Principal  
Colby Biomedical Ventures

Grant Colfax, M.D.  
Director  
Marin Health and Human Services  
San Rafael, California

Elizabeth Connick, M.D.  
Professor of Medicine  
Chief, Division of Infectious Diseases  
Department of Medicine  
University of Arizona

Deborah Jean Cotton, M.D., M.P.H.  
Professor of Medicine  
Boston University School of Medicine

Bryan R. Cullen, Ph.D., D.Sc.  
James B. Duke Professor  
Department of Molecular Genetics and Microbiology  
Director, Duke University Center for Virology  
Duke University Medical Center

Susanna Cunningham-Rundles, Ph.D.  
Professor Emerita of Research Immunology  
Department of Pediatrics  
Weill Cornell Medical College

Richard Thomas D'Aquila, M.D.  
The Howard Taylor Ricketts Professor of Medicine  
Division of Infectious Diseases  
Director, Northwestern HIV Translational Research Center  
Feinberg School of Medicine  
Northwestern University

Steven Deeks, M.D.  
Professor  
Department of Medicine  
University of California, San Francisco

Sherry Deren, Ph.D.  
Co-Director  
Center for Drug Use and HIV Research  
New York University College of Nursing

Roger Detels, M.D., M.S.  
Professor of Epidemiology  
School of Public Health  
University of California, Los Angeles

Carl W. Dieffenbach, Ph.D.  
Director  
Division of AIDS (DAIDS)  
National Institute of Allergy and Infectious Diseases  
National Institutes of Health

D. Peter Drotman, M.D., M.P.H.  
Editor-in-Chief  
Emerging Infectious Diseases  
Centers for Disease Control and Prevention

Anke A. Ehrhardt, Ph.D.  
Director  
Division of Gender, Sexuality, & Health  
Program for the Study of LGBT Health  
NYS Psychiatric Institute/Columbia University

Jacob Estes, Ph.D.  
Principal Scientist/Principal Investigator  
AIDS and Cancer Virus Program (ACVP)  
Frederick National Laboratory for Cancer Research  
National Cancer Institute

Homayoon Farzadegan, Ph.D.  
Professor  
Department of Epidemiology  
Johns Hopkins Bloomberg School of Public Health

Dianne M. Finkelstein, Ph.D.  
Professor of Biostatistics  
Harvard School of Public Health  
Director of the Cancer Center Biostatistics  
Massachusetts General Hospital

Gerald Herbert Friedland, M.D.  
Professor and Director  
AIDS Care Program  
Department of Internal Medicine  
Yale School of Medicine

Rémi Fromentin, Pharm.D., Ph.D.  
Postdoctoral Researcher  
Université de Montréal, Centre de Recherche du CHUM

Howard E. Gendelman, M.D.  
Professor and Chair, Department of Pharmacology and Experimental Neuroscience  
Margaret R. Larson Professor of Internal Medicine and Infectious Diseases  
Director, Center for Neurodegenerative Disorders  
University of Nebraska Medical Center

Nancy L. Haigwood, Ph.D.  
Director and Senior Scientist  
Division of Pathobiology and Immunology  
Oregon National Primate Research Center  
Oregon Health and Science University

Timothy Henrich, M.D.  
Assistant Professor of Medicine  
Division of Infectious Disease  
University of California, San Francisco

Charles H. Hinkin, Ph.D.  
Professor  
Department of Psychiatry and Biobehavioral Sciences  
David Geffen School of Medicine  
University of California, Los Angeles

David Ho, M.D.  
Scientific Director, Chief Executive Officer  
Aaron Diamond AIDS Research Center

**Thomas J. Hope, Ph.D.**  
Professor  
Department of Cell and Molecular Biology  
Feinberg School of Medicine  
Northwestern University

**Shiu-Lok Hu, Ph.D.**  
Professor  
School of Pharmacy  
University of Washington

**Jonathan Karn, Ph.D.**  
Director  
Center for AIDS Research  
Case Western Reserve University

**Vineet KewalRamani, Ph.D.**  
Chief, Model Development Section  
HIV Drug Resistance Program  
National Cancer Institute  
National Institutes of Health

**Hans-Peter Kiem, M.D., F.A.C.P.**  
Full Member, Clinical Research Division  
Jose Carreras/E. Donnell Thomas Endowed  
Chair for Cancer Research  
Fred Hutchinson Cancer Research Center  
Seattle, WA

**Scott Kitchen, Ph.D.**  
Assistant Professor of Medicine  
Division of Hematology and Oncology  
David Geffen School of Medicine  
University of California, Los Angeles

**Richard Kornbluth, M.D., Ph.D.**  
President and Chief Scientific Officer  
Multimeric Biotherapeutics, Inc.

**Richard A. Koup, M.D.**  
Deputy Director, Vaccine Research Center  
Chief, Immunology Laboratory  
National Institute of Allergy and Infectious  
Diseases  
National Institutes of Health

**Nathaniel R. Landau, Ph.D.**  
Professor  
Department of Microbiology  
New York University School of Medicine

**Alan L. Landay, Ph.D.**  
Professor and Chairman  
Department of Immunology and Microbiology  
Rush-Presbyterian-St. Luke's Medical Center

**Michael Lederman, M.D.**  
Scott R. Inkley Professor of Medicine  
Associate Director, Center for AIDS Research  
Case Western Reserve University

**Tun-Hou Lee, D.Sc.**  
Professor of Virology, Emeritus  
Department of Immunology and Infectious  
Diseases  
Harvard School of Public Health

**Michael J. Leibowitz, M.D., Ph.D.**  
Professor, Medical Microbiology and Immunology  
University of California, Davis

**Robert J. Levine, M.D.**  
Professor of Medicine  
Center for Interdisciplinary Research on AIDS  
Yale University

**Sharon Lewin, F.R.A.C.P., Ph.D.**  
Director  
Peter Doherty Institute for Infection and Immunity  
University of Melbourne

**Mathias Lichterfeld, M.D.**  
Assistant Professor of Medicine  
Massachusetts General Hospital

**Judy Lieberman, M.D., Ph.D.**  
Senior Investigator  
Immune Disease Institute  
Professor of Pediatrics  
Harvard Medical School

**H. Kim Lyerly, M.D.**  
Professor in Surgery, Immunology, Pathology  
George Barth Geller Chair of Cancer Research  
Director of the Center of Applied Therapeutics  
Duke Cancer Institute  
Duke University Medical Center

**Frank Maldarelli, M.D., Ph.D.**  
Investigator  
HIV DRP Host-Virus Interaction Branch  
National Cancer Institute  
National Institutes of Health

**David M. Margolis, M.D.**  
Professor of Medicine, Microbiology and  
Immunology, and Epidemiology  
School of Medicine  
University of North Carolina at Chapel Hill

**Martin H. Markowitz, M.D.**  
Professor and Clinical Director  
Aaron Diamond AIDS Research Center

**Kenneth Hugh Mayer, M.D.**  
Infectious Disease Attending & Director of HIV  
Prevention Research  
Beth Israel Deaconess Medical Center  
  
Professor of Medicine  
Harvard Medical School

Medical Research Director, Co-Chair  
The Fenway Institute/Fenway Health

**Joseph M. McCune, M.D., Ph.D.**  
Professor of Medicine  
Chief, Division of Experimental Medicine  
University of California, San Francisco

**Donna Mildvan, M.D.**  
Chief, Division of Infectious Diseases  
Department of Medicine  
Beth Israel Medical Center

**Jay A. Nelson, Ph.D.**  
Professor and Director  
Vaccine and Gene Therapy Institute  
Oregon Health and Science University

**Una O'Doherty, M.D., Ph.D.**  
Associate Professor  
Department of Pathology and Laboratory Medicine  
Perelman School of Medicine  
University of Pennsylvania

**Nancy Padian, Ph.D., M.P.H.**  
Adjunct Professor of Epidemiology  
School of Public Health  
University of California, Berkeley

**Savita Pahwa, M.D.**  
Professor of Microbiology and Immunology  
Professor in Pediatrics and Medicine  
Director of the Miami Center for AIDS Research  
University of Miami Leonard M. Miller School of  
Medicine

**Tristram G. Parslow, M.D., Ph.D.**  
William Patterson Timmie Professor and Chair  
Department of Pathology and Laboratory Medicine  
Emory University School of Medicine

**Matija Peterlin, M.D.**  
Professor of Medicine, Microbiology and  
Immunology  
Department of Medicine  
University of California, San Francisco

**Lynn Pulliam, Ph.D.**  
Professor  
Department of Laboratory Medicine and Medicine  
University of California, San Francisco  
Veterans Affairs Medical Center

**Lee Ratner, M.D., Ph.D.**  
Professor  
Department of Medicine  
Washington University School of Medicine

**Andrew Rice, Ph.D.**  
Professor  
Department of Molecular Virology and  
Microbiology  
Baylor College of Medicine

**Charles Rinaldo, Ph.D.**  
Professor and Chair  
Infectious Diseases and Microbiology  
University of Pittsburgh

**Melissa Robbiani, Ph.D.**  
Senior Scientist and Director of Biomedical HIV  
Research  
Center for Biomedical Research  
Population Council

**Ruth M. Ruprecht, M.D., Ph.D.**  
Scientist, Department of Virology and Immunology  
Southwest National Primate Research Center  
Director, Texas Biomed AIDS Research Program  
Texas Biomedical Research Institute

**Sarah Schlesinger, M.D.**  
Associate Professor of Clinical Investigation  
Laboratory of Molecular Immunology  
The Rockefeller University

**Frederick A. Schmitt, Ph.D.**  
Professor  
Departments of Neurology, Psychiatry, and  
Psychology and Behavioral Science  
Sanders Brown Center on Aging  
University of Kentucky

**Gerald Schochetman, Ph.D.**  
Senior Director, Diagnostics Research  
Abbott Laboratories

**Robert Turner Schooley, M.D.**  
Academic Vice Chair  
Professor and Head  
Department of Medicine/Division of Infectious  
Diseases  
University of California, San Diego

## PROGRAM ADVISORY COUNCIL

**Gail Skowron, M.D.**  
Professor of Medicine  
Boston University School of Medicine

**Serena Spudich, M.D., M.A.**  
Associate Professor of Neurology  
Division Chief, Neurological Infections  
and Global Neurology  
Department of Neurology  
Yale School of Medicine

**Leonidas Stamatatos, Ph.D.**  
Member  
Fred Hutchinson Cancer Research Center  
Vaccine and Infectious Disease Division  
Immunology and Vaccine Development Program  
Seattle, WA

**Mario Stevenson, Ph.D.**  
Professor of Medicine  
Chief, Division of Infectious Diseases  
University of Miami Leonard M. Miller School  
of Medicine

**Susana Valente, Ph.D.**  
Associate Professor  
Department of Immunology and Microbial  
Sciences  
The Scripps Research Institute

**Barbara Visscher, M.D., Dr.P.H.**  
Professor of Epidemiology  
University of California, Los Angeles

**David Vlahov, Ph.D., R.N.**  
Professor of Nursing,  
Epidemiology, and Biostatistics  
University of California, San Francisco

**David J. Volsky, Ph.D.**  
Professor of Medicine and Pathology  
Icahn School of Medicine at Mount Sinai

Director of Molecular Virology Laboratory  
Department of Medicine  
Mount Sinai St. Luke's and Roosevelt Hospitals

**Steven S. Witkin, Ph.D.**  
Professor of Immunology  
Department of Obstetrics and Gynecology  
Weill Cornell Medical College

**Peter R. Wolfe, M.D.**  
Associate Clinical Professor  
David Geffen School of Medicine  
University of California, Los Angeles

**Steven Wolinsky, M.D.**  
Professor  
Medicine/Infectious Diseases  
Feinberg School of Medicine  
Northwestern University

**Richard T. Wyatt, Ph.D.**  
Professor of Immunology  
IAVI Center for Neutralizing Antibodies  
The Scripps Research Institute

**Jerome Zack, Ph.D.**  
Professor  
Department of Medicine  
David Geffen School of Medicine  
University of California, Los Angeles

**Mervyn F. Silverman, M.D., M.P.H. (Chairman)**  
President  
Mervyn F. Silverman Associates  
Crockett, CA

**Judith D. Auerbach, Ph.D.**  
Science and Policy Consultant and Professor  
School of Medicine  
University of California, San Francisco

**David Bloom, Ph.D.**  
Clarence James Gamble Professor of Economics  
and Demography  
Department of Global Health and Population  
Harvard School of Public Health  
Boston, MA

**Tim Brown, Ph.D.**  
Senior Fellow  
The East-West Center  
Honolulu, HI

**Daniel Douek, M.D., Ph.D.**  
Chief, Human Immunology Section  
Vaccine Research Center  
National Institute of Allergy and Infectious  
Diseases  
National Institutes of Health

**Daria J. Hazuda, Ph.D.**  
Vice President, Scientific Affairs for Infectious  
Disease  
Merck & Company, Inc.  
West Point, PA

**Kenneth Hugh Mayer, M.D.**  
Infectious Disease Attending & Director of HIV  
Prevention Research  
Beth Israel Deaconess Medical Center

Professor of Medicine  
Harvard Medical School

Medical Research Director, Co-Chair  
The Fenway Institute/Fenway Health

**Mario Stevenson, Ph.D.**  
Professor of Medicine  
Chief, Division of Infectious Diseases  
University of Miami Leonard M. Miller School of  
Medicine

**Jeffrey L. Sturchio, Ph.D.**  
Senior Partner  
Rabin Martin  
New York, NY

Visiting Scholar  
The Institute for Applied Economics, Global Health  
and the Study of Business Enterprise  
Johns Hopkins University

Member  
The Council on Foreign Relations  
Washington, D.C.

**Phill Wilson**  
Chief Executive Officer and President  
The Black AIDS Institute  
Los Angeles, CA

## MANAGEMENT GROUP

**Kevin Robert Frost**  
Chief Executive Officer

**Anthony Ancona**  
Vice President and Director, Human Resources

**Susan J. Blumenthal, M.D., M.P.A.**  
Senior Policy and Medical Advisor

**Bradley Jensen**  
Chief Financial Officer

**Rowena Johnston, Ph.D.**  
Vice President and Director, Research

**Jeffrey Laurence, M.D.**  
Senior Scientific Consultant for Programs

**John F. Logan, Ph.D., J.D.**  
Vice President and General Counsel

**Gregorio Millett, M.P.H.**  
Vice President and Director, Public Policy

**Eric Muscatell**  
Vice President, Development

**AnnMari Shannahan**  
Vice President, Public Information

**Annette Sohn, M.D.**  
Vice President and Director, TREAT Asia

**amfAR, The Foundation for AIDS Research**

**NEW YORK**

120 Wall Street, 13th Floor  
New York, NY 10005-3908  
(212) 806-1600 (tel)  
(212) 806-1601 (fax)

**WASHINGTON, D.C.**

1100 Vermont Avenue, NW  
Suite 600  
Washington, DC 20005  
(202) 331-8600 (tel)  
(202) 331-8606 (fax)

**BANGKOK, THAILAND**

TREAT Asia  
Exchange Tower  
388 Sukhumvit Road, Suite 2104  
Klongtoey, Bangkok 10110  
Thailand  
+66 (0)2 663 7561 (tel)  
+66 (0)2 663 7562 (fax)

**[www.amfar.org](http://www.amfar.org)**



[bbb.org/charity](http://bbb.org/charity)

amfAR meets the BBB  
Wise Giving Alliance's  
Standards for Charity  
Accountability.



★★★★  
**CHARITY NAVIGATOR**  
Four Star Charity



**COMMUNITY**  
HEALTH CHARITIES